Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
about
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database studyDecision analysis for the cost-effective management of recurrent colorectal cancerPositron emission tomography and colorectal cancer.Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review.A simulation model of colorectal cancer surveillance and recurrence.Diagnostic and prognostic value of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography for colorectal cancer: comparison with conventional computed tomography.FDG-PET/CT Is Superior to Enhanced CT in Detecting Recurrent Subcentimeter Lesions in the Abdominopelvic Cavity in Colorectal CancerValue of Surveillance (18)F-FDG PET/CT in Colorectal Cancer: Comparison with Conventional Imaging Studies.Treated Colorectal Cancer: What is the Cost to Primary Care?Oncologic positron emission tomography: a surgical perspective.Diagnostic imaging approaches and relationship to hepatobiliary cancer staging and therapy.The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.The impact of new technology on surgery for colorectal cancer.FDG-PET in colorectal cancer.Clinical applications of FDG-PET in oncology.18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomographyThe role of positron emission tomography in the management of colorectal cancer.The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma.The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operatiWhole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer.FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEACombined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer.Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis.Background Colonic 18F-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography Is Associated with the Presence of Colorectal Adenoma.Positron emission tomography: clinical applications in oncology. Part 1.Management of recurrent colorectal cancer with positron emission tomography.The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.Imaging as a surveillance tool in rectal cancer.Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise?Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients.Factors influencing [F-18] 2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity.Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer.The clinical use of PET--where are we now?[18F-fluorodeoxyglucose positron emission tomography in colorectal cancer: value in primary staging and follow-up]Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes.Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
P2860
Q28354043-A8C38F68-FF7C-4C77-A5D2-07EB7ABB3F32Q28354061-2F81AC22-9F6E-47DB-84E0-BD3FBD639060Q31893861-3E8E3E8B-38D5-4B9C-BFCE-8F7F6AC021D2Q33612653-A4657D46-B05A-44F1-9947-6061C809BD13Q33613715-3A1D2F85-8C3F-467F-80C9-1313A4E50D0BQ33679151-8298C852-04FC-464A-A12C-4F1493979D6BQ33704466-A8D934D7-DDCD-4BF2-94FC-99EFBC598733Q33704530-6B681FB6-FFA9-4FA5-BB27-0B4534D61B39Q33860288-1EAA95A8-0D50-408B-AE34-04E746A132A4Q33945401-DB8BFFA0-5EC0-40C8-8BB0-64C946864ADDQ34111000-052C4869-8CEB-48F4-8261-EFB5F0C10814Q34471196-A42316A2-C936-4EDA-9FFA-2D3E1B99B556Q34512138-423B2370-D149-4CF0-B5A9-04C6EBBE5432Q34572647-430D559E-696C-4F88-8DF6-8DFA0133953EQ35036165-041C9844-F05A-48A3-82C7-5A3FC6C1BE19Q35127213-A3C0C549-4BC4-449A-BD66-4F28D52D132EQ35596074-43B8A859-756B-49FE-87DE-4AE1102AF64EQ35615005-5AE2A770-E686-4A2E-9F53-D31954F85DC0Q35687578-78214646-4292-4288-A907-C5FC3F1D43B2Q35751527-0C23E97A-735B-4B4D-9F17-F692257C87F0Q35760809-89C0905F-C5C5-4D45-98E4-8F5C08EC7D05Q35850832-FD0C6389-4227-43EC-B8C3-0AEFB5C4EF07Q35928605-421989C1-7E2D-4089-8356-2809819BFE29Q36086546-411FF940-86BD-4988-845B-4582F20E6602Q36100290-3160AE17-0881-49C0-8526-B645E97F7E39Q36334917-3E435EC0-582C-4E50-911D-C88DA2D95E22Q37035077-A37E2BC8-5756-461C-A394-F68987DD77A2Q37328589-6DEC2B7D-9540-4747-BE68-6688853121AEQ37658819-75CC23C8-7E87-4723-8E45-7995E2991785Q37768890-D72079F6-BB89-4004-83E5-F75A44AF48F6Q38429784-1BE84D01-372A-4C67-87AD-C6E8BE41CCE4Q40393387-CB8DCEC8-E28C-4ECC-BF79-037EF41B6923Q42739703-D8590F7D-2700-4823-8DE3-0F247F4E843DQ42780962-26857B14-3C2E-4998-8A6C-000E38CCFC07Q43627692-3D8CC352-1A39-497D-94F4-D4A37663C83CQ44266134-15418992-EB03-48F4-A7E3-F4B3A80B673EQ45023757-A302658C-D1FC-49E9-9911-B8265C5C75FCQ46503577-19B614BB-8575-4A76-9F80-1BB2BE676B00Q48028704-84C58133-F097-4A90-9375-1DB0B45806B2Q51201268-FA718165-F8F8-454B-BB74-0624F93DAF54
P2860
Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Whole-body PET imaging with [1 ...... f recurrent colorectal cancer.
@en
type
label
Whole-body PET imaging with [1 ...... f recurrent colorectal cancer.
@en
prefLabel
Whole-body PET imaging with [1 ...... f recurrent colorectal cancer.
@en
P2093
P1433
P1476
Whole-body PET imaging with [1 ...... f recurrent colorectal cancer.
@en
P2093
Abella-Columna E
Haseman MK
P304
503-11; discussion 511-3
P356
10.1001/ARCHSURG.134.5.503
P577
1999-05-01T00:00:00Z